

Product Data Sheet

Product Name: SNX3-IN-1

Cat. No.: GC81346

Chemical Properties

Cas. No. 2344793-72-0

Formula $C_{23}H_{24}O_6$ M.Wt 396.43

Solubility DMSO: 50 mg/mL (126.13 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.


Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Structure



Background

SNX3-IN-1 is a sorting nexin 3 (SNX3) inhibitor. SNX3-IN-1 reduces SNX3 protein expression and inhibits SNX3-mediated activation of the Wnt/ β -catenin signaling pathway. SNX3-IN-1 inhibits the proliferation and migration of pulmonary fibrosis-related cells, and decreases the expression of fibrosis markers α -SMA and COL-1. SNX3-IN-1 can be used in research related to pulmonary fibrosis [1].

In Vivo, SNX3-IN-1 (Compound LC4) (10 mg/kg; intratracheal administration; once weekly for 3 consecutive weeks) effectively ameliorates Wnt/ β -catenin pathway activation, pulmonary function impairment and fibrosis in a mouse model of pulmonary fibrosis^[1].

In Vitro, SNX3-IN-1 (Compound LC4) inhibits the enhanced migratory capacity of fibroblasts overexpressing SNX3^[1]. SNX3-IN-1 inhibits SNX3-induced β -catenin accumulation and nuclear

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

localization in cells^[1]. SNX3-IN-1 (10 μ M) inhibits TGF- β 1-induced α -SMA expression in AT2 cells and fibroblasts, thereby reducing fibrotic activation^[1].

References:

[1]. Ma D, et al. Targeting sorting nexin 3 to treat pulmonary fibrosis by dual modulating Wnt/ β -catenin signaling. Cell Death Dis. 2026;17(1):43. Published 2026 Jan 15.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA